Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Sep 07, 2026
TickeronGET DAILY SIGNALS
Medline (MDLN) Holds Near $36–37 Range as Revenue Climbs but Profits Face Pressure

Medline (MDLN) Holds Near $36–37 Range as Revenue Climbs but Profits Face Pressure

Key Takeaways

  • Medline shares have been roughly flat over the trailing 30 days, holding near the $36–37 range after a volatile summer that saw the stock slide from its early-August highs.
  • Second-quarter 2026 revenue rose 11.6% year over year to $7.7 billion, while net income fell 58.3% amid tariff headwinds and higher operating costs.
  • Management raised full-year organic sales growth guidance to 9%–10% but lowered its adjusted EBITDA outlook to $3.3–$3.4 billion, underscoring persistent margin pressure.
  • Multiple sell-side firms trimmed price targets following the Q2 report, while the broader analyst consensus remains a Buy with a 12-month target near $44.62.
  • Regulatory scrutiny, including two FDA warning letters and an ongoing securities investigation, remains a key overhang on investor sentiment.

Where MDLN Stands in the Market Right Now

MDLN has traded in a relatively narrow band over the past 30 days, hovering in the mid-$30s after a sharp drawdown in early August pulled shares from above $42 to the low-$30s. The stock has since stabilized and recovered modestly, though it remains well below its post-IPO high of $50.88 and down year to date. With a market capitalization of roughly $48 billion and an average daily volume in the millions of shares, Medline is one of the more closely watched names in the healthcare supplies sector, yet its shares continue to reflect investor concerns about profitability rather than revenue momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Understanding Medline’s Operations and Market Position

Medline is the largest provider of medical-surgical products and supply chain solutions in the United States, generating more than 90% of its revenue domestically while serving some of the country's largest health systems. The company operates through two segments: Medline Brand, which procures and manufactures products across surgical solutions, front-line care, and laboratory and diagnostics, and Supply Chain Solutions, which distributes third-party national-brand products and offers logistics and optimization services.

Founded in 1966 and headquartered in Northfield, Illinois, Medline offers approximately 190,000 Medline-branded products across more than 250 product families, alongside roughly 150,000 third-party products sourced from more than 1,250 vendors. Its scale is reinforced by more than 30 manufacturing facilities and a fleet of more than 2,000 owned delivery trucks, supporting prime vendor relationships that make the company a consolidated logistics partner for many customers. Medline completed its initial public offering on the Nasdaq in December 2025, and investors follow the stock for its exposure to defensive, recurring healthcare demand as well as its efforts to navigate cost inflation and tariff exposure.

What Drove Recent Moves in MDLN Shares

Medline's second-quarter 2026 results, reported in early August, captured the tension between top-line strength and bottom-line pressure that has defined the stock's recent trading. Net sales climbed 11.6% to $7.7 billion, and adjusted EBITDA rose 13.4% to $1.1 billion, but net income dropped 58.3% to $139 million as tariff costs, inflation, and operational investments weighed on profitability. Adjusted EPS of $0.50 exceeded consensus estimates of $0.32.

Management raised its full-year organic sales growth outlook to 9%–10%, up from a prior 8.5%–9.5%, citing strong demand and new customer wins. At the same time, the company reduced its adjusted EBITDA guidance to $3.3–$3.4 billion from $3.5–$3.6 billion, reflecting inflation, costs tied to the Tracy fire, and planned operational investments.

In response, numerous analysts lowered their price targets while largely maintaining constructive ratings. JPMorgan, TD Cowen, Morgan Stanley, and BMO Capital were among the firms trimming targets, with the consensus price target settling near $44.62. The stock has also contended with negative catalysts, including two FDA warning letters issued within a two-month span over quality lapses and a securities investigation announced by Kaplan Fox & Kilsheimer LLP. A regulatory filing disclosed that GIC Private Ltd, a holder of more than 10% of shares, sold 1.5 million shares in mid-August, adding to supply-related pressure. From what I see, these regulatory and institutional moves warrant close attention.

2026 Outlook and What Investors Should Watch

Heading into the remainder of 2026, Medline's trajectory will likely hinge on its ability to defend margins while sustaining high-single-digit organic sales growth. Key areas to monitor include the evolution of tariff and inflation costs, the financial impact and remediation timeline associated with the FDA warning letters and the ongoing securities investigation, and any further updates to full-year adjusted EBITDA guidance.

Investors should also watch demand trends across the healthcare provider landscape, the pace of new customer wins and prime vendor relationships, and management's cost-saving initiatives aimed at offsetting margin erosion. Competitive dynamics within medical-surgical distribution and the potential for further institutional share movements following the GIC sale round out the factors that could shape sentiment in the months ahead. I’m watching this closely as the company works through these issues.

Integrating AI Tools Into My Research Process

When evaluating names like MDLN, I often turn to Tickeron’s AI Trading Bots to test different systematic approaches alongside my own fundamental review. The platform surfaces a range of strategies that can help compare short-term signals with longer-term trend ideas, which adds another layer to how I assess risk and opportunity in the healthcare sector. It is one way I try to stay disciplined when volatility or regulatory news creates uncertainty.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MDLN

MDLN's RSI Oscillator leaves overbought zone

The 10-day RSI Indicator for MDLN moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 instances where the indicator moved out of the overbought zone. In 3 of the 3 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDLN as a result. In 10 of 11 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for MDLN turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 6 similar instances when the indicator turned negative. In 5 of the 6 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

MDLN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

MDLN moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MDLN crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +3.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDLN advanced for three days, in 40 of 55 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

The Aroon Indicator entered an Uptrend today. In 32 of 43 cases where MDLN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. MDLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.005) is normal, around the industry mean (4.964). P/E Ratio (49.592) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (0.966) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Industry
N/A
Address
3 Lakes Drive
Phone
+1 847 949-5500
Employees
45000
Web
https://www.medline.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.